Tasisulam-induced suicidal death of human erythrocytes Authors: Abdulla Al Mamun Bhuyan, Md Ashraf Zaman Faruk, Md Niamot Ali, Md Abu Choudhury, Mengzhou Xue, Chunfu Zheng, Florian Lang Published: 2026 ABSTRACT AbstractTasisulam, an acyl-sulfonamide compound, is being investigated in clinical trials for the treatment of several malignancies, including non-small cell lung cancer, lymphoma, breast cancer, melanoma, ovarian cancer, colon cancer, and other solid tumors, by promoting apoptosis. However, anemia is among the adverse consequences of tasisulam therapy and is potentially caused by increased eryptosis or premature erythrocyte senescence, characterized by cell contraction and phosphatidylserine (PS) translocation. Underlying signals associated with eryptosis include increased intercellular calcium activity ([Ca2+]i), oxidative stress, excess ceramide production, and stimulation of various kinases (protein kinase C, p38 kinase, casein kinase-1, etc.) or caspases. This research investigated the potential of tasisulam to induce eryptosis and its underlying signaling pathways. Human erythrocytes (0.4%) were incubated with 75, 150, or 300 μg/ml tasisulam for 48 h at 37°C. Flow cytometry revealed that tasisulam (≥300 μg/ml) significantly increased erythrocyte apoptosis, [Ca2+]i, reactive oxygen species (ROS), and ceramide formation without causing cell membrane shrinkage. The effect of tasisulam on erythrocyte death was significantly reduced by the removal of extracellular calcium or the inhibition of casein kinase. In conclusion, tasisulam triggers eryptosis by stimulating calcium influx, ceramide generation, oxidative stress, and casein kinase 1 activation, which may be associated with tasisulam-associated anemia.Keywords: Eryptosis, Tasisulam, Casein kinase 1, Oxidative stress, Calcium Introduction Tasisulam sodium (N-(2,4-dichlorobenzoyl)-5-bromothiophene-2-sulfonamide), commonly referred to as tasisulam, is a novel chemotherapeutic agent with activity against several malignancies, including leukemia, melanoma, and cancers of the breast, lung, kidney, colon, and ovary [1]. The antitumor effects of tasisulam are achieved mainly through apoptosis and the inhibition of angiogenesis [2,3]. In nucleated cells, it promotes oxidative stress, leading to the release of cytochrome C from mitochondria and subsequent activation of the intrinsic apoptotic pathway via caspase-9. Furthermore, tasisulam increases the fraction of cells with 4 N DNA content and phospho-histone H3 expression in both in vitro and in vivo cancer models, followed by the promotion of G2-M phase arrest and apoptosis [2]. Tasisulam-induced apoptosis is further enhanced by its unique ability to suppress major prosurvival signaling factors, including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF) [2,3]. Clinical trials of tasisulam have revealed several adverse effects, most notably anemia [2,4]. Although eryptosis or suicide erythrocyte death is a common physiological event, it is considered one of the potential causes of anemia [5,6]. The distinctive characteristics of eryptosis include either cellular contraction or the translocation of phosphatidylserine to the outer leaflet of the cell membrane or both [5,7]. Its signaling pathways are multifactorial and involve cation channel activation with increased intracellular Ca2+ concentrations ([Ca2+]i), ceramide formation, oxidative stress, energy depletion, and the activation of caspases as well as several kinases, including p38 kinase, casein kinase 1α, protein kinase C, and Janus kinase-3 [5,8]. Upregulated eryptosis has been implicated in a wide range of clinical disorders, such as diabetes, arteritis, sepsis, sickle cell anemia, thalassemia, glucose-6-phosphate dehydrogenase deficiency, febrile illness, liver injury, cardiac arrest, renal disease, hemolytic uremic syndrome, dehydration, inflammation, and phosphate depletion [5,9]. Considering that numerous xenobiotics have been demonstrated to induce eryptosis, investigating whether tasisulam has a similar effect on erythrocytes is worthwhile. Therefore, the present study aimed to assess the ability of tasisulam to cause eryptosis. For this purpose, tasisulam was applied to healthy human erythrocytes, and key features of eryptosis, including PS externalization on the cell membrane, cell size, intracellular Ca2+ levels, ceramide formation, and ROS generation, were assessed via flow cytometry. Materials and methods Erythrocytes, chemicals, and solutions Fresh human blood samples were obtained from the University of Tübingen Blood Bank via Li-heparinized tubes, with prior approval from the institutional ethics committee (approval no. 184/2003 V). Whole blood was centrifuged at 120 × g for 20 min at 21°C, and the supernatant containing leukocytes and platelets was carefully discarded. For in vitro experiments, erythrocytes were adjusted to 0.4% and cultured in Ringer's solution without (control) or with different concentrations of tasisulam (Selleckchem, Munich, Germany). The cultures were maintained for 48 h (h) at 37°C to induce eryptosis. To assess the potential solvent effect, erythrocytes were also incubated with dimethyl sulfoxide (DMSO). The composition of Ringer's solution was as follows: 125 mM NaCl, 1 mM MgSO4, 5 mM KCl, 32 mM HEPES (pH 7.4), 5 mM glucose, and 1 mM CaCl2. In separate experimental settings, isolated erythrocytes (RBCs) were incubated with tasisulam in the presence or absence of extracellular calcium. To investigate the contribution of signaling pathways, cells were further treated with or without the following inhibitors: the casein kinase inhibitor D4476 (10 μM; Tocris Bioscience, Bristol, UK), the protein kinase C inhibitor chelerythrine (1 μM; Tocris Bioscience), the p38 kinase inhibitor SB203580 (2 μM; Tocris), and the caspase inhibitor emricasan (10 μM; Selleckchem, Munich, Germany) [10]. Measurement of annexin-V After 48 h of incubation, 150 μl of the erythrocyte suspension was centrifuged at 1600 rpm for 3 min, and the supernatant was carefully discarded. The erythrocyte pellet was resuspended and stained with annexin-V fluorescein isothiocyanate (Annexin-V FITC; 1:200 dilution; ImmunoTools, Friesoythe, Germany). The stained samples were further incubated for 15 min at 37°C in the dark to prevent photobleaching. Following incubation, annexin-V positive erythrocytes were analyzed via flow cytometry (BD Biosciences, Heidelberg, Germany) at excitation and emission wavelengths of 488 nm and 530 nm, respectively. For analysis, the annexin-V positive and control populations were distinguished via an artificial marker (M1) [10]. Measurement of erythrocyte volume Erythrocyte volume was determined by assessing forward scatter (FSC) signals obtained from flow cytometry. After treatment and incubation, 150 μl of erythrocyte suspension was transferred to a multi-well plate and subsequently loaded into fluorescence-activated cell sorting (FACS) tubes without staining via a multichannel pipette. FSC values were recorded and compared with side scatter (SSC) signals on a linear dot plot. The geometric mean (GM) of FSC intensity was used to quantify erythrocyte volume, with a value of 500 arbitrary units fixed for the control group. A rightward shift from the control indicated cell swelling, whereas a leftward shift reflected erythrocyte shrinkage [10]. Measurement of cytosolic Ca2+ in erythrocytes After 48 h of incubation, 150 μL of erythrocyte suspension was washed once with Ringer's solution and subsequently loaded with the fluorescent calcium indicator Fluo-3/AM (5 μM; Biotium, Hayward, USA) for 30 min at 37°C. Following incubation, the cells were rinsed again with Ringer solution containing 5 mM CaCl2 to remove excess dye and ensure optimal loading. Intracellular Ca2+-dependent fluorescence was then quantified via a FACS Calibur flow cytometer (FL-1 channel), and the geometric mean fluorescence intensity was calculated [10]. Measurement of oxidative stress Intracellular oxidative stress was assessed by quantifying reactive oxygen species (ROS) via 2′,7′-dichlorodihydrofluorescein diacetate (2′,7′-DCFDA; Sigma‒Aldrich, Hamburg, Germany). Briefly, 150 μL of erythrocyte suspension was washed and incubated with 10 μM DCFDA for 30 min at 37°C. The cells were then rinsed twice with Ringer's solution, and ROS-associated fluorescence was measured in the FL-1 channel of the FACS Calibur flow cytometer [10]. Estimation of ceramide abundance Following the incubation period, 100 μl of erythrocyte suspension was stained with a mouse anti-ceramide antibody (clone MID 15B4; Alexis, Grünberg, Germany) at a dilution of 1:10 and incubated for 1 h at 37°C. Phosphate-buffered saline (PBS) supplemented with 0.1% bovine serum albumin (BSA) was used as the diluent. After incubation, the cells were washed twice with PBS-BSA and subsequently stained with a FITC-conjugated polyclonal goat anti-mouse IgG/IgM secondary antibody (1:50; BD Pharmingen, Hamburg, Germany) for 30 min at 37°C. Excess unbound antibody was removed by washing with PBS-BSA. Ceramide abundance was quantified by measuring the fluorescence intensity via the FL-1 channel of a flow cytometer, and the results are expressed as the geometric mean fluorescence intensity (geoMFI) to compare control and tasisulam-treated samples [10]. Statistical analysis The data are presented as the means ± standard errors of the means (SEMs). Statistical comparisons between groups were performed via either Student's t-test or one-way analysis of variance (ANOVA), followed by Tukey's post hoc test where appropriate. The number of independent experiments is indicated by 'n'. Identical erythrocyte samples were used without replication for both the experimental and control conditions to minimize inter-sample variability. Results This study first evaluated whether tasisulam induces eryptosis, which is characterized by erythrocyte condensation and the externalization of phosphatidylserine (PS). PS exposure was quantified by annexin-V binding via flow cytometry. The isolated erythrocytes were incubated with tasisulam (75-300 μg/ml) for 48 h, after which the proportion of annexin-V positive cells was determined. As shown in Fig. 1, treatment with 300 μg/ml tasisulam for 48 h resulted in a significant increase in the number of PS-exposed erythrocytes compared with that in the untreated control or vehicle (DMSO) groups, and the lower concentrations (75 and 150 μg/ml) had no measurable effect. Impact of tasisulam on the translocation of phosphatidylserine. A. Initial histogram of erythrocyte annexin-V binding after 48 h of incubation in Ringer's solution without (blue region) and with (red line) 300 μg/ml tasisulam. B. The arithmetic means ± SEMs (n = 20) of erythrocyte annexin-V binding, which was obtained after 48 h of incubation in Ringer's solution without (blue bars) or with (red bars) tasisulam (75-300 μg/ml). The effect of the solvent DMSO is displayed for comparison (gray bar). ANOVA revealed a significant difference (***(P < 0.0001)) compared with the absence of tasisulam. Cell shrinkage is a well-established feature of eryptosis. To assess whether tasisulam induces this phenotype, erythrocytes were incubated at 75-300 μg/ml for 48 h and analyzed by forward scatter flow cytometry. The mean cell volume in the treated groups (75 μg/ml: 482.4 ± 12.3 a.u. (n = 14); 150 μg/ml: 474.4 ± 9.7 a.u. (n = 20); 300 μg/ml: 509.5 ± 8.5 a.u. (n = 20)) did not differ significantly from that in the controls (498.2 ± 8.6 a.u., n = 20). These results demonstrate that tasisulam does not induce erythrocyte shrinkage (Fig. 2A). Effect of tasisulam on cytosolic Ca2+ activity in erythrocytes. A. The original histogram shows the Fluo3 fluorescence of erythrocytes after they were incubated for 48 h in Ringer's solution without (blue region) or with (red line) 300 μg/ml tasisulam. B. The arithmetic means ± SEMs (n = 20) of erythrocyte Fluo-3 fluorescence following a 48-h incubation period in Ringer's solution without (blue bar) or with (red bars) tasisulam (75-300 μg/ml). The effect of the solvent DMSO is displayed for comparison (gray bar). ANOVA revealed a significant difference (***(P < 0.0001)) compared with the absence of tasisulam. Cytosolic Ca2+, a central regulator of eryptosis, was quantified via Fluo-3 fluorescence. To evaluate whether tasisulam altered intracellular calcium homeostasis, erythrocytes were incubated with increasing concentrations of the compound (75-300 μg/ml) for 48 h. The baseline fluorescence in the untreated cells was 17.5 ± 0.7 a.u. (n = 20). Comparable values were observed at 75 μg/ml (17.9 ± 0.7 a.u., n = 20) and 150 μg/ml (19.7 ± 0.9 a.u., n = 20), indicating that there was no appreciable effect at lower concentrations. In contrast, treatment with 300 μg/ml tasisulam resulted in a pronounced increase in fluorescence (32.3 ± 1.2 a.u., n = 20; P < 0.01), reflecting a significant increase in cytosolic Ca2+ levels (Fig. 2B). These findings suggest that tasisulam promotes calcium influx in erythrocytes in a concentration-dependent manner, with marked effects occurring only at higher doses. To determine whether Ca2+ influx is required for tasisulam-induced phosphatidylserine translocation, erythrocytes were incubated with or without tasisulam (300 μg/ml) in the absence or presence of extracellular calcium. As shown in Fig. 3, the sensitivity of erythrocytes to tasisulam-induced eryptosis was significantly attenuated under calcium-free conditions. Nevertheless, tasisulam still markedly increased the fraction of eryptotic erythrocytes even in the absence of extracellular Ca2+. These findings indicate that tasisulam-induced phosphatidylserine translocation is only partially dependent on extracellular Ca2+ influx. Ca2+ sensitivity of tasisulam to the externalization of phosphatidylserine. A-B. Original histograms showing erythrocyte annexin-V binding after 48 h of incubation in Ringer's solution without (blue areas) and with (red lines) tasisulam (300 μg/ml) in the presence (A) and absence (B) of extracellular Ca2+. C. Arithmetic means ± SEMs (n = 10) of erythrocyte annexin-V binding following a 48-h treatment with Ringer's solution in the presence (left bars, +Ca2+) or absence (right bars, -Ca2+) of Ca2+ with tasisulam (300 μg/ml) (red bars). ANOVA revealed that there was a significant difference between the presence of Ca2+ (###P<0.0001) and the absence of tasisulam (***P < 0.0001). Previous studies have demonstrated that oxidative stress can stimulate eryptosis. To evaluate this mechanism, oxidative stress in the control and tasisulam-treated (300 μg/ml) groups was assessed via DCFDA fluorescence. As shown in Fig. 4, exposure to tasisulam significantly enhanced DCFDA fluorescence, indicating an elevated level of oxidative stress within RBCs. Effect of tasisulam on the generation of reactive oxygen species (ROS) in erythrocytes. A. This histogram shows DCFDA fluorescence in erythrocytes after 48 h of exposure to Ringer's solution without or with 300 μg/ml tasisulam. The blue area represents the fluorescence without tasisulam, and the red line represents the fluorescence with tasisulam. B. The graph shows the arithmetic means ± SEMs (n = 10) of DCFDA fluorescence in erythrocytes after a 48-h incubation in Ringer's solution without (blue bar) or with (red bar) tasisulam (300 μg/ml). According to the paired t-test, ***(P<0.0001) denotes a significant difference from the absence of tasisulam. Ceramide is another established calcium-independent trigger of eryptosis. To explore its role, ceramide abundance was quantified after erythrocytes were incubated with or without tasisulam (300 μg/ml) for 48 h. Fig. 5 shows that ceramides were significantly elevated in erythrocytes following exposure to tasisulam. Effect of tasisulam on the formation of ceramide in erythrocytes. A. Histogram displaying ceramide-dependent fluorescence in erythrocytes following 48 h of exposure to Ringer's solution without and with 300 μg/ml tasisulam (blue region and red line, respectively). B. Arithmetic means ± SEMs (n = 5) of ceramide-dependent fluorescence in erythrocytes after 48 h of incubation in Ringer's solution without (blue bar) or with (red bar) tasisulam (300 μg/ml). A significant difference from the lack of tasisulam is shown by ***(P < 0.0001) in the paired t-test. Tasisulam-induced eryptosis was further investigated in the presence and absence of protein kinase inhibitors. Erythrocytes were incubated with 300 μg/ml tasisulam either without or with chelerythrine (1 μM; PKC inhibitor), D4476 (10 μM; CK1α inhibitor), or SB203580 (2 μM; p38 kinase inhibitor). As shown in Figs. 6 and 7A-B, tasisulam significantly increased the number of annexin-V positive cells. Neither PKC inhibition with chelerythrine nor p38 inhibition with SB203580 significantly altered tasisulam-induced PS exposure, indicating that these kinases are not essential for this process. In contrast, inhibition of CK1α with D4476 significantly reduced eryptosis (22.33 ± 2.16% to 7.5 ± 1.0%, P < 0.0001), although residual annexin-V positivity persisted (P < 0.05). These findings suggest that CK1α contributes to but is not solely responsible for tasisulam-triggered suicidal erythrocyte death. Role of Casein kinase 1 inhibitor (D4476) in tasisulam-induced phosphatidylserine exposure. The original histograms of annexin-V binding of erythrocytes after 48 h of exposure to Ringer's solution without (blue area) and with (red line) tasisulam (300 μg/ml) are shown in Figures A and B, respectively, both in the absence and presence of the casein kinase inhibitor D4476 (10 μM). The arithmetic means± SEMs (n = 5) of annexin-V binding of erythrocytes after a 48-h treatment in Ringer's solution without (blue bar) or with (red bar) tasisulam (300 μg/ml), both in the absence (-D4476) and presence (+D4476) of the casein kinase inhibitor D4476 (10 μM), are shown in Figure C. ***(P<0.0001), *(P < 0.05) indicates a significant difference from the absence of tasisulam, whereas #(P < 0.05) indicates a significant difference from the presence of D4476 (10 μM). To evaluate the potential role of caspases, erythrocytes were exposed to 300 μg/ml tasisulam in the presence or absence of the pancaspase inhibitor emricasan (10 μM). As shown in Fig. 7C, tasisulam significantly increased the percentage of annexin-V positive cells, and this effect was not attenuated by caspase inhibition (16.4 ± 2.6% vs. 17.7 ± 2.8%, respectively; n = 5). These results indicate that tasisulam-induced eryptosis occurs independently of caspase activation. Role of protein kinase C, p38 kinase, or caspases in tasisulam-induced PS exposure. A. Arithmetic means ± SEMs (n = 5) of erythrocyte annexin-V binding following a 48-h treatment with Ringer's solution without (blue bar) and with (red bar) tasisulam (300 μg/ml), both in the absence (-chelerythrine) and presence (+chelerythrine) of the protein kinase C inhibitor chelerythrine (1 μM). ***(P < 0.0001) indicates a significant difference from the absence of tasisulam. B. Arithmetic means ± SEMs (n = 5) of erythrocyte annexin-V binding following 48 h of treatment with Ringer's solution without (blue bar) or with (red bar) tasisulam (300 μg/ml), both in the absence (-SB203580) and presence (+SB203580) of the p38 kinase inhibitor SB203580 (2 μM). ***(P < 0.0001) indicates a significant difference from the absence of tasisulam. C. Arithmetic means ± SEMs (n = 5) of erythrocyte annexin-V binding following 48 h of treatment with Ringer's solution without (blue bar) or with (red bar) tasisulam (300 μg/ml), both in the absence (-emricasan) and presence (+emricasan) of the caspase inhibitor emricasan (10 μM). ***(P < 0.0001) indicates a significant difference from the absence of tasisulam. Discussion According to the current investigation, tasisulam causes the breakdown of membrane phospholipids through the translocation of phosphatidylserine, a vital feature of eryptosis. Tasisulam stimulates eryptosis, an entirely novel finding linking chemotherapy with tasisulam and subsequent anemia. The necessary concentrations of tasisulam required to induce eryptosis are in line with values (up to 420 μg/ml) reported in patients' blood plasma [1,4,11]. Thus, anemia after tasisulam treatment may result from increased eryptosis. Notably, for this in vitro basic experiment, we considered only the maximum plasma concentration of tasisulam but not the free or plasma-bound tasisulam. Various clinical conditions, such as beta-thalassemia [12], sickle-cell disease [13], dehydration [14], hyperphosphatemia [15], iron deficiency [16], hemolytic-uremic syndrome [17], diabetes [18], liver diseases [7], cancer [19], sepsis [9], Hb-C and G6PD deficiency [20], and Wilson's disease [21], increase erythrocyte death before senescence. Increased intraerythrocytic calcium is a vital regulator of eryptosis. Increased cytosolic calcium causes membrane scrambling and externalization of PS and breaks down the cytoskeleton, resulting in blebbing of the cell membrane [10]. The influence of tasisulam on PS translocation was enforced by increased intracellular calcium activity ([Ca2+]i), reflecting stimulation of the nonselective cation channel (NSCC) and the entrance of Ca2+ from the extracellular environment. The eryptosis caused by tasisulam was attenuated when extracellular Ca2+ was removed. However, the orientation of the cell membrane could still change because of a shortage of extracellular calcium, suggesting the involvement of additional mechanisms in tasisulam-induced eryptosis. Additionally, ceramide can potentially sensitize the externalization of membrane phosphatidylserine by activating the scramblase enzyme [22]. Ceramide-mediated eryptosis is independent and does not rely on the regulation of cytosolic calcium. The results of the present investigation revealed that tasisulam significantly increased the generation of ceramides in erythrocytes. Reactive oxygen species (ROS) are known triggers of ferroptosis [23]. Oxidative stress or ROS stimulate NSCC, resulting in Ca2+ entry into erythrocytes, membrane scrambling, and PS translocation [23]. In the present study, tasisulam significantly increased the generation of ROS in erythrocytes. Thus, tasisulam is effective at causing oxidative stress to some extent. Although protein kinase C and p38 kinase coordinate eryptosis, they seem unnecessary for tasisulam-induced eryptosis. Another kinase, casein kinase-1α (CK1α), is a well-known mediator of eryptosis [24]. The CK1α inhibitor D4476 moderately but significantly reduced tasisulam-induced cell membrane scrambling. Caspases may or may not contribute to the stimulation of eryptosis, depending on the activator [25]. Oxidative stress is among the known activators of caspases in erythrocytes, causing the anion exchanger AE1 to cleave, followed by decreased Cl− and HCO3− exchange, hyperpolarization of cells, and eryptosis [26,27]. Although tasisulam generated ROS in erythrocytes in the present study, it did not induce eryptosis through the activation of emricasan-sensitive caspases. As erythrocytes do not possess mitochondria, they cannot use the mitochondrial pathway to activate caspases. The studied erythrocytes did not shrink significantly in response to tasisulam. As tasisulam substantially increases the level of intracellular calcium, it is predicted to open calcium-sensitive potassium channels (Gardos channels), followed by the exit of K+ and Cl and membrane hyperpolarization, resulting in a decrease in the amount of intracellular water and cell shrinkage [9]. The mechanism by which signaling prevents tasisulam-induced erythrocyte shrinkage remains elusive. However, possible explanations include the inactivation of the Gardos channel, the lack of inactivation of Na+/K + ATPase, or the prevention of ATP depletion following tasisulam exposure. Anemia is a common side effect of chemotherapy or the treatment of malignancies with cytostatic substances. Although diverse signaling pathways are associated with the development of anemia in cancer patients following chemotherapy, numerous studies have demonstrated that increased eryptosis induced by cytostatic drugs is a significant cause of anemia in cancer patients [9]. Our tested compound, tasisulam, has also been reported to cause anemia following chemotherapy [4], and in the present study, we found that tasisulam stimulates eryptosis. Therefore, further in vivo investigations of tasisulam-treated cancer patients are needed to confirm the involvement of tasisulam in eryptosis and to elucidate the mechanism of anemia in more detail. In vivo, eryptosis aims to remove damaged erythrocytes from the bloodstream before hemolysis occurs, thereby protecting the kidney by preventing the deposition of hemoglobin in the kidney tubules [5,28]. The clearance of phosphatidylserine-exposing erythrocytes can lead to anemia when the loss of red blood cells is more pronounced than the generation of new cells through erythropoiesis [29]. Phosphatidylserine-exposed or eryptotic erythrocytes can further attach to the vascular endothelium, resulting in the stimulation of blood coagulation [30], the formation of thrombi [31,32], and, finally, the interference of microcirculation [33], suggesting that further investigations of the effects of tasisulam on erythrocytes are needed to avoid any unwanted possible complications following chemotherapy. In conclusion, our investigation revealed that tasisulam induces eryptosis via the upregulation of Ca2+ influx, oxidative stress, ceramide formation, and D4476-sensitive casein kinase 1. However, this is considered a basic study, and further research is needed, particularly in vivo or in patients receiving chemotherapy with tasisulam and hematopoietic stem cells, to fully understand the implications of our research findings. Many unanswered questions in this field remain to be investigated, and we wish to continue this important work. Consent to participate Written consent was obtained from the blood donors. Consent to publish Not applicable. Ethics approval Ethical approval was received from the University of Tübingen's ethical approval committee (184/2003 V). Additional information All the information is available for this paper. Declaration of using AI-assisted technologies during the development of the manuscript ChatGPT (version 5.2) was used to refine the sentence structure and improve the academic writing style, whereas QuillBot and Grammarly were utilized to minimize grammatical errors. After these tools/services were used, the manuscript was reviewed and edited again as necessary. Funding statement Grants from the Deutsche Forschungsgemeinschaft have supported this research. CRediT authorship contribution statement Abdulla Al Mamun Bhuyan: Data curation, Formal analysis, Investigation, Validation, Visualization, Writing – original draft. Md Ashraf Zaman Faruk: Formal analysis, Writing – review & editing. Md Niamot Ali: Formal analysis, Writing – original draft. Md Abu Choudhury: Formal analysis, Writing – review & editing. Mengzhou Xue: Project administration, Writing – review & editing. Chunfu Zheng: Conceptualization, Project administration, Writing – review & editing. Florian Lang: Conceptualization, Project administration, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments The authors thank the University of Tübingen Blood Bank and the Deutsche Forschungsgemeinschaft for funding this research. Contributor Information Mengzhou Xue, Email: xuemengzhou@zzu.edu.cn. Chunfu Zheng, Email: zheng.alan@hotmail.com. Florian Lang, Email: florian.lang@uni-tuebingen.de. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.